Table 1.
Most targeted antigen in clinical trials in solid tumor CAR T cell therapy
| Antigen | Cancer | Phase | ID |
|---|---|---|---|
| EGFR | Lung, liver, stomach | Phase 1/2 | NCT03179007, NCT03525782 |
| HER2 | Central nervous system tumor, pediatric glioma | Phase 1 | NCT03500991 |
| EGFR806 | Central nervous system tumor, pediatric glioma | Phase 1 | NCT03179012 |
| Mesothelin | Ovarian, cervical, pancreatic, lung | Phase 1/2 | NCT01583686 |
| PSCA | Lung | Phase 1 | NCT03198052 |
| MUC1 | Advanced solid tumors, lung | Phase 1/2 | NCT03179007, NCT03525782 |
| Claudin 18.2 | Advanced solid tumor | Phase 1 | NCT03874897 |
| EpCAM | Colon, pancreatic, prostate, gastric, liver | Phase 1/2 | NCT03013712 |
| GD2 | Brain | Phase 1 | NCT04099797 |
| VEGFR2 | Melanoma, brain | Phase 1 | NCT01218867 |
| AFP | Hepatocellular carcinoma liver cancer | Phase 1 | NCT03349255 |
| Nectin4/FAP | Nectin4-positive advanced malignant solid tumor | Phase 1 | NCT03932565 |
| CEA | Lung, colorectal, gastric, breast, pancreatic cancer | Phase 1 | NCT02349724 |
| Lewis Y | Advanced cancer | Phase 1 | NCT03851146 |
| Glypican-3 | Liver | Phase 1 | NCT02932956 |
| EGFRIII | Glioblastoma and brain tumor | Phase 1 | NCT01454596 |
| IL-13Rα2 | Glioblastoma | Phase 1 | NCT02208362 |
| CD171 | Neuroblastoma | Phase 1 | NCT02311621 |
| MUC16 | Ovarian | Phase 1 | NCT02311621 |
| PSMA | Prostate | Phase 1 | NCT01140373 |
| AFP | Hepatocellular carcinoma, liver | Phase 1 | NCT03349255 |
| AXL | Renal | Phase 1 | NCT03393936 |
| CD20 | Melanoma | Phase 1 | NCT03893019 |
| CD80/86 | Lung | Phase 1 | NCT03198052 |
| c-MET | Breast, hepatocellular | Phase 1 | NCT03060356, NCT03638206 |
| DLL-3 | Lung | Phase 1 | NCT03392064 |
| DR5 | Hepatoma | Phase 1 | NCT03638206 |
| EpHA2 | Glioma | Phase 1 | NCT02575261 |
| FR-α | Ovarian | Phase 1 | NCT00019136 |
| gp100 | Melanoma | Phase 1 | NCT03649529 |
| MAGE-A1/3/4 | Lung | Phase 1 | NCT03356808, NCT03535246 |
| LMP1 | Nasopharyngeal | Phase 1 | NCT02980315 |
EGFR epidermal growth factor receptor, HER2 human epidermal growth factor receptor 2, PSCA prostate stem cell antigen, MUC1 mucin1, EpCAM epithelial cell adhesion molecule, AFP alpha-fetoprotein, FAP familial adenomatous polyposis, CEA carcinoembryonic antigen, MUC16 mucin16, PSMA prostate-specific membrane antigen, AXL AXL receptor tyrosine kinase, DLL3 delta-like 3, EPHA2 EPH receptor A2, FRα folate receptor alpha, LMP1 Epstein-Barr virus latent membrane protein 1, MAGE melanoma antigen gene protein, DR5 death receptor 5